![Samantha Vieira](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Aktive Positionen von Samantha Vieira
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Anjarium Biosciences AG
![]() Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | Geschäftsführer | 12.07.2022 | - |
Karriereverlauf von Samantha Vieira
Ehemalige bekannte Positionen von Samantha Vieira
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
BIOGEN INC. | Corporate Officer/Principal | 01.06.2019 | 01.08.2021 |
Statistik
International
Schweiz | 2 |
Vereinigte Staaten | 2 |
Operativ
Chief Operating Officer | 1 |
Corporate Officer/Principal | 1 |
Sektoral
Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
BIOGEN INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
Anjarium Biosciences AG
![]() Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | Health Technology |
- Börse
- Insiders
- Samantha Vieira
- Erfahrung